Fly News Breaks for February 6, 2020
Feb 6, 2020 | 07:10 EDT
Cantor Fitzgerald analyst Alethia Young raised her price target for Arrowhead Pharmaceuticals to $55 from $50 after the company reported Q1 earnings and provided clinical updates. The company released its first interim patient data for two cardio-metabolic programs, ARO-APOC3 and ANGPTL3, Young tells investors in a research note. She keeps a Neutral rating on Arrowhead.
News For ARWR From the Last 2 Days
There are no results for your query ARWR